艾伯维公司 ABBV 深 沪
等待开盘 05-11 09:30:00 美东时间
201.145
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 201.145
- 总市值 3.55亿
- 52周最高 244.49
- 市盈率 静 31.17
- 换手率 0.00%
- 52周最低 180.25
- 委 比 0.00%
- 总股本 0.02亿
- 历史最高 244.49
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.78
- 每 手 1
- 风险率 16.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AbbVie Thanks 'Excellent Start To 2026' To Immunology And Neuroscience Strength
AbbVie Q1 2026 sales beat estimates as Skyrizi and Rinvoq drive growth, while Humira declines; company raises full-year EPS outlook.
04-30 02:49
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
The FDA flags manufacturing issues in AbbVie wrinkle drug filing; no safety concerns, response planned, $1.4 billion plant announced.
04-24 20:46
Nxera Pharma Receives $10M Payment From AbbVie Under Its 2022 Multi-Target Discovery Partnership
Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting
04-20 21:37
FDA Takes Step Forward on Testosterone Therapy for Men
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
04-16 23:37
Healthcare, Financials ETFs Get A Mega-Cap Reset With TRUF, TRUH
A closer look at VanEck's new TRUF and TRUH ETFs, designed to deliver cleaner healthcare and financials exposure with minimal tracking error.
04-07 04:40
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth
AbbVie beat Q4 earnings and sales estimates, driven by strong Skyrizi and Rinvoq growth. The drugmaker raised its 2026 outlook despite falling Humira sales and mixed results in aesthetics.
02-05 01:38
UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
01-29 01:07
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
01-28 18:51
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse
Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement.
01-26 19:01
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-16 01:35
